ProQR Therapeutics N.V. Logo

ProQR Therapeutics N.V.

Biotech developing RNA-editing therapies for genetic disorders using the body's own enzymes.

PRQR | US

Overview

Corporate Details

ISIN(s):
NL0010872495
LEI:
Country:
United States of America
Address:
ZERNIKEDREEF 9, LEIDEN
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

ProQR Therapeutics N.V. is a biotechnology company dedicated to the discovery and development of RNA therapies for severe rare and common genetic disorders. The company's core focus is its proprietary Axiomer® RNA-editing technology platform. This platform is designed to make targeted edits to RNA by recruiting the body's own ADAR (Adenosine Deaminase Acting on RNA) enzymes, representing a novel approach to treating diseases with high unmet medical needs. ProQR advances its technology through in-house research and development as well as strategic partnerships, including a major collaboration with Eli Lilly and Company to discover, develop, and commercialize new medicines.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all ProQR Therapeutics N.V. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ProQR Therapeutics N.V.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ProQR Therapeutics N.V. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

IMPACT BIOMEDICAL INC. Logo
Develops biopharma, preservatives, and bioplastics for healthcare and pathogen protection.
United States of America
IBO
Imunon, Inc. Logo
Developing DNA-based immunotherapies for oncology and infectious diseases.
United States of America
IMNN
IN8BIO, INC. Logo
Clinical-stage biopharma developing gamma-delta T cell therapies for solid & hematological tumors.
United States of America
INAB
Develops targeted dermatology & oncology therapies using unique formulation & delivery technologies.
United Kingdom
INC
INCYTE CORP Logo
Develops proprietary therapeutics for serious unmet needs in oncology and inflammation.
United States of America
INCY
Indaptus Therapeutics, Inc. Logo
Develops immunotherapies using engineered bacteria to treat cancer and viral infections.
United States of America
INDP
Indivior PLC Logo
Develops pharmaceuticals for opioid use disorder, addiction, and serious mental illnesses.
United Kingdom
INDV
Infant Bacterial Therapeutics Logo
Develops live bacterial medicines to prevent rare, severe gut diseases in premature infants.
Sweden
IBT
InflaRx N.V. Logo
Develops complement system inhibitors for severe inflammatory diseases and immuno-dermatology.
United States of America
IFRX
Inhibikase Therapeutics, Inc. Logo
Develops kinase inhibitors to treat neurodegenerative diseases like Parkinson's.
United States of America
IKT

Talk to a Data Expert

Have a question? We'll get back to you promptly.